Image Place holder

Kenneth H. Shain, MD, PhD


Specialty: Medical Oncology
Program: Malignant Hematology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Shain is an Assistant Member at H. Lee Moffitt Cancer Center in the Departments of Malignant Hematology, Tumor Biology, and the Chemical Biology and Molecular Medicine Program. He also has an appointment as an Assistant Professor at the University of South Florida Morsani College of Medicine, in the Department of Oncologic Sciences. Dr. Shain is a clinician scientist with time divided by clinic, clinic trials, and translational research with primary focus in multiple myeloma and other plasma cell related disorders (including Waldenstrom Macroglobulinemia and Primary Amyloidosis).  Dr. Shain has been a resident of the Tampa Bay area for over 35 years, first arriving in St. Petersburg for undergraduate education at Eckerd College. He then earned his PhD under the mentorship of William Dalton, PhD, MD at Moffitt and the USF College of Medicine. Dr. Shain then enrolled in Medical School at USF and completed his internal medicine and hematology/oncology fellowship training via an accelerated translational research track at USF & Moffitt, respectively; thus supporting his career goals to carry-out bench to bedside care and research for myeloma patients as well as the education of physicians and scientists of tomorrow.  Currently, Dr. Shain serves as the Scientific Director of the Moffitt Myeloma Working Group (MMWG). 

Education & Training

Board Certification:

  • Medical Oncology

Fellowship:

  • University of South Florida College of Medicine, Moffitt Cancer Center - Hematology/Oncology

Residency:

  • University of South Florida College of Medicine - Internal Medicine

Medical School:

  • University of South Florida College of Medicine - MD
Participating Trials

CLINICAL TRIAL 19001
A Phase 1a/1b Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CWP232291 Administered Intravenously Either Alone or in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed or Refractory Myeloma (MM)
Condition: Malignant Hematology
Intervention: CC-5013 (Lenalidomide); CWP232291; Dexamethasone; Lenalidomide (Revlimid)
Open

CLINICAL TRIAL 19079
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination with Pomalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention: CC-4047 (Pomalidomide); Dexamethasone; Oprozomib; Pomalidomide
Open

CLINICAL TRIAL 19230
Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib,and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation
Condition: Malignant Hematology
Intervention: Bortezomib; CC-5013 (Lenalidomide); Daratumumab; Dexamethasone; Lenalidomide (Revlimid); PS-341 (Bortezomib); Velcade (Bortezomib)
Open

CLINICAL TRIAL 18430
Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation
Condition: Malignant Hematology
Intervention: Panobinostat (LBH589)
Open

CLINICAL TRIAL 18346
Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation
Condition: Malignant Hematology
Intervention: G-CSF; Prevnar13; Survivin-Dendritic Cell Vaccine
Open

CLINICAL TRIAL 18891
A Multinational Open-Label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients with Different Metastatic Tumor Types
Condition: Malignant Hematology
Intervention: NKR-2
Open

CLINICAL TRIAL 18630
Phase 1/2 Investigator Sponsored Study of Selinexor in Combination with High-Dose Melphalan Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Dexamethasone; KPT-330 (Selinexor); Melphalan; Selinexor
Open

CLINICAL TRIAL 19093
Open-Label Randomized Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination with Pembrolizumab in HLA-A2+ Subjects with NY-ESO-1 and/or LAGE-1a Positive Relapsed and Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention: NY-ESO-1c259T; Pembrolizumab (Keytruda); cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Fradley MG, Groarke JD, Laubach J, Alsina M, Lenihan DJ, Cornell RF, Maglio M, Shain KH, Richardson PG, Moslehi J. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. Brit J Haematol. 2017 Oct. Pubmedid: 29048105.
  • Rollison DE, Komrokji R, Lee JH, Hampras S, Fulp W, Fisher K, Baz R, Nishihori T, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Sullivan D, Alsina M, Dalton W, Shain KH. Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide. Leuk Lymphoma. 2017 Mar;58(3):560-568. Pubmedid: 27424609.
  • Silva AS, Silva MC, Sudalagunta P, Distler AI, Jacobson T, Collins A, Nguyen T, Song J, Chen DT, Chen L, Cubitt CL, Baz R, Perez L, Rebatchouk D, Dalton W, Greene J, Gatenby RA, Gillies RJ, Sontag E, Meads MB, Shain K. An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma. Cancer Res. 2017 Jun;77(12):3336-3351. Pubmedid: 28400475.
  • Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol. 2017 Jan;18(1):112-121. Pubmedid: 27927582.
  • Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, Zhang L, Fu K, Bi C, Li J, Jiang H, Meads MB, Jacobson T, Silva M, Distler A, Darville L, Zhang L, Han Y, Rebatchouk D, Di Liberto M, Moscinski LC, Koomen JM, Dalton WS, Shain KH, Wang M, Sotomayor E, Tao J. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017 Apr;8:14920. Pubmedid: 28416797. Pmcid: PMC5399304.
  • Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. 2016 Nov;7(48):78896-78909. Pubmedid: 27806331. Pmcid: PMC5340237.
  • Meads MB, Fang B, Mathews L, Gemmer J, Nong L, Rosado-Lopez I, Nguyen T, Ring JE, Matsui W, MacLeod AR, Pachter JA, Hazlehurst LA, Koomen JM, Shain KH. Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma. Oncogene. 2016 May;35(21):2723-2734. Pubmedid: 26387544. Pmcid: PMC4801703.
  • Baz RC, Martin TG, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 May;127(21):2561-2568. Pubmedid: 26932802.
  • Rollison DE, Shain KH, Lee JH, Hampras SS, Fulp W, Fisher K, Al Ali NH, Padron E, Lancet J, Xu Q, Olesnyckyj M, Kenvin L, Knight R, Dalton W, List A, Komrokji RS. Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide. Cancer Med. 2016 Jul;5(7):1694-1701. Pubmedid: 27098006. Pmcid: PMC4944897.
  • Turner JG, Dawson JL, Grant S, Shain KH, Dalton WS, Dai Y, Meads M, Baz R, Kauffman M, Shacham S, Sullivan DM. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J Hematol Oncol. 2016 Aug;9(1):73. Pubmedid: 27557643. Pmcid: PMC4997728.
  • Nishihori T, Song J, Shain KH. Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment. Curr Hematol Malig Rep. 2016 Apr;11(2):118-126. Pubmedid: 26898557. Pmcid: PMC4819726.
  • Shain KH, Dalton WS, Tao J. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene. 2015 Sep;34(36):4673-4682. Pubmedid: 25639873. Pmcid: PMC4688902.
  • Griffin PT, Ho VQ, Fulp W, Nishihori T, Shain KH, Alsina M, Baz RC. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. Cancer. 2015 Oct;121(20):3622-3630. Pubmedid: 26149422.
  • Nishihori T, Baz R, Shain K, Kim J, Ochoa-Bayona JL, Yue B, Sullivan D, Dalton W, Alsina M. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma. Eur J Haematol. 2015 Nov;95(5):426-435. Pubmedid: 25600676. Pmcid: PMC4508238.
  • Fang B, Hoffman MA, Mirza AS, Mishall KM, Li J, Peterman SM, Smalley KS, Shain KH, Weinberger PM, Wu J, Rix U, Haura EB, Koomen JM. Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. Methods. 2015 Jun;81:41-49. Pubmedid: 25782629. Pmcid: PMC4460980.
  • Silva A, Jacobson T, Meads M, Distler A, Shain K. An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells. J Vis Exp. 2015 Jul;(101):e53070. Pubmedid: 26274375. Pmcid: PMC4544963.
  • Nishihori T, Hassoun Y, Zhang L, Shain K, Alsina M, Kharfan-Dabaja MA. High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation. Bone Marrow Transplant. 2014 Jan;49(1):148-149. Pubmedid: 23933759.
  • Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst L, Perez L, Baz R, Shain K, Silva AS. A preclinical assay for chemosensitivity in multiple myeloma. Cancer Res. 2014 Jan;74(1):56-67. Pubmedid: 24310398. Pmcid: PMC3915502.
  • Baz RC, Shain KH, Hussein MA, Lee JH, Sullivan DM, Finleyoliver E, Nardelli LA, Nodzon LA, Zhao X, Ochoa-Bayona JL, Nishihori T, Dalton WS, Alsina M. Phase II study of pegylated liposomal doxorubicin, low-dose dexamethasone, and lenalidomide in patients with newly diagnosed multiple myeloma. Am J Hematol. 2014 Jan;89(1):62-67. Pubmedid: 24030918. Pmcid: PMC4522918.
  • Shain KH, Tao J. The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies. Oncogene. 2014 Aug;33(32):4107-4113. Pubmedid: 24037527. Pmcid: PMC4669099.
  • Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B. Sequence of novel agents in multiple myeloma: an instrumental variable analysis. Leuk Res. 2013 Sep;37(9):1077-1082. Pubmedid: 23809054.
  • Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, Anasetti C, Alsina M. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma. Bone Marrow Transplant. 2013 Sep;48(9):1179-1184. Pubmedid: 23542223. Pmcid: PMC4500071.
  • Boucher K, Parquet N, Widen R, Shain K, Baz R, Alsina M, Koomen J, Anasetti C, Dalton W, Perez LE. Stemness of B-cell progenitors in multiple myeloma bone marrow. Clin Cancer Res. 2012 Nov;18(22):6155-6168. Pubmedid: 22988056. Pmcid: PMC3500436.
  • Sugimori C, Padron E, Caceres G, Shain K, Sokol L, Zhang L, Tiu R, O'Keefe CL, Afable M, Clemente M, Lee JM, Maciejewski JP, List AF, Epling-Burnette PK, Araten DJ. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation. Blood Cancer J. 2012 Mar;2(3):e63. Pubmedid: 22829258. Pmcid: PMC3317526.
  • Nishihori T, Alekshun TJ, Shain K, Sullivan DM, Baz R, Perez L, Pidala J, Kharfan-Dabaja MA, Ochoa-Bayona JL, Fernandez HF, Yarde DN, Oliveira V, Fulp W, Han G, Kim J, Chen DT, Raychaudhuri J, Dalton W, Anasetti C, Alsina M. Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma. Brit J Haematol. 2012 Jun;157(5):553-563. Pubmedid: 22449149. Pmcid: PMC4030553.
  • Shain K. Metastatic myeloma?. Blood. 2012 Jun;119(24):5612-5613. Pubmedid: 22700691.
  • Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, Koomen JM. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma. Mol Cell Proteomics. 2011 Nov;10(11):M110.005520. Pubmedid: 21846842. Pmcid: PMC3226396.
  • Lebovic D, Zhang L, Alsina M, Nishihori T, Shain KH, Sullivan D, Ochoa-Bayona JL, Kharfan-Dabaja MA, Baz R. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience. Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):507-511. Pubmedid: 21813352.
  • Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, Dalton WS. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 2009 Feb;69(3):1009-1015. Pubmedid: 19155309. Pmcid: PMC2680075.
  • Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, Beg AA, Dalton WS. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma. Cancer Res. 2009 Dec;69(24):9367-9375. Pubmedid: 19934314. Pmcid: PMC4519834.
  • Shain KH, Dalton WS. Environmental-mediated drug resistance: a target for multiple myeloma therapy. Expert Rev Hematol. 2009 Dec;2(6):649-662. Pubmedid: 21082957.
  • Perez L, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C, Dalton W. Bone Marrow Stroma Confers Resistance to Apo2 Ligand/TRAIL in Multiple Myeloma inPart by Regulating c-FLIP. J Immunol. 2008 Feb;180(3):1545-1555. Pubmedid: 18209050.
  • Burdelya L, Kujawski M, Niu G, Zhong B, Wang T, Zhang S, Kortylewski M, Shain K, Kay H, Djeu J, Dalton W, Pardoll D, Wei S, Yu H. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J Immunol. 2005 Apr;174(7):3925-3931. Pubmedid: 15778348. Pmcid: PMC2632804.
  • Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004;10(1):48-54. Pubmedid: 14702634.
  • Dalton W, Hazlehurst L, Shain K, Landowski T, Alsina M. Targeting the bone marrow microenvironment in hematologic malignancies. Semin Hematol. 2004;41(2):1-5. Pubmedid: 15190509.
  • Hazlehurst L, Enkemann S, Beam C, Argilagos R, Painter J, Shain K, Saporta S, Boulware L, Moscinski L, Alsina M, Dalton W. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 2003 Nov;63(22):7900-7906. Pubmedid: 14633719.
  • Chen T, Yang I, Irby R, Shain K, Wang H, Quackenbush J, Coppola D, Cheng JQ, Yeatman T. Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Res. 2003;63(15):4368-4374. Pubmedid: 12907606.
  • Shain K, Landowski T, Dalton W. Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J Immunol. 2002;168(5):2544-2553. Pubmedid: 11859150.
  • Shain K, Dalton W. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther. 2001;1(1):69-78. Pubmedid: 12467240.
  • Niu G, Shain K, Huang M, Ravi R, Bedi A, Dalton W, Jove R, Yu H. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res. 2001;61(8):3276-3280. Pubmedid: 11309279.
  • Shain KH, Landowski TH, Buyuksal I, Cantor AB, Dalton WS. Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia. 2000 May;14(5):830-840. Pubmedid: 10803514.
  • Shain K, Landowski T, Dalton W. The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance. Curr Opin Oncol. 2000;12(6):557-563. Pubmedid: 11085455.
  • Anderson K, Kyle R, Dalton W, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J. Multiple Myeloma: New Insights and Therapeutic Approaches. Hematology Am Soc Hematol Educ Program. 2000;147-165. Pubmedid: 11701540.
  • Shain K, Jove R, Olashaw N. Constitutive Rel B activity in v-Src transformed fibroblasts: requirement for lkB degradation. J Cell Biochem. 1999 May;73(2):237-247. Pubmedid: 10227387.
  • Landowski T, Shain K, Oshiro M, Buyuksal I, Painter J, Dalton W. Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. Blood. 1999 Jul;94(1):265-274. Pubmedid: 10381522.
  • Azizan A, Cong Y, Shain K, Tsai S, Olashaw N, Seto E. Transactivation by expression of the hepatitis B virus X protein with an inducible system. Mol Biol Rep. 1998 Nov;25(4):231-236. Pubmedid: 9870613.